NCT06927050

Brief Summary

This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
86

participants targeted

Target at P25-P50 for not_applicable cancer

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 8, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 15, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

April 21, 2025

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2026

Completed
Last Updated

February 25, 2026

Status Verified

February 1, 2026

Enrollment Period

12 months

First QC Date

April 8, 2025

Last Update Submit

February 23, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of "Satisfied" Patients

    Patients will take a 9-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; patients with 6 or more "Yes" answers out of 9 questions are defined as "Satisfied" patients.

    Day 0

Secondary Outcomes (2)

  • Percentage of "Satisfied" Caregivers

    Day 0

  • Percentage of "Satisfied" Providers

    Day 0

Study Arms (1)

Patients (and caregivers) recently diagnosed with cancer

EXPERIMENTAL

Enrolled patients will receive a tool during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. Following the encounter, a survey will be provided. If patients are accompanied by a caregiver(s), they will also receive a survey.

Behavioral: Visual Communication Tool

Interventions

MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.

Also known as: MyCareGorithm
Patients (and caregivers) recently diagnosed with cancer

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients:
  • Patients seen in consultation from 12/1/2024-6/1/2025
  • Patients aged 18 years to 100 years old
  • Patients with a malignancy of breast or head and neck
  • English speaking patients
  • Patients being treated with definitive intent
  • Patients treated at NYU Langone Health for their malignancy
  • Willing and able to provide consent
  • Caregivers:

You may not qualify if:

  • Willing and able to provide consent
  • Providers:
  • Doctors and nurse practitioners in medical oncology and radiation oncology, and in the ear nose throat (ENT) department.
  • Willing and able to provide consent
  • aged 18 years to 100 years old
  • Patients:
  • Patients with any other site of disease other than listed above
  • Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process.
  • Patient unable to complete the survey portion of the study independently
  • Caregivers:
  • Unable to complete the survey portion of the study independently

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Jason Domogauer, MD, PhD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 8, 2025

First Posted

April 15, 2025

Study Start

April 21, 2025

Primary Completion

April 1, 2026

Study Completion

April 1, 2026

Last Updated

February 25, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jason.Domogauer@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access Criteria
The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Jason.Domogauer@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

Locations